2018
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) † † These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO).
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, Saghir N, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) † † These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO). Annals Of Oncology 2018, 29: 1634-1657. PMID: 30032243, PMCID: PMC7360146, DOI: 10.1093/annonc/mdy192.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, Large-Core NeedleBreastBreast NeoplasmsChemoradiotherapy, AdjuvantClinical Trials as TopicConsensus Development Conferences as TopicEuropeEvidence-Based MedicineFemaleHumansIntegrative MedicineMastectomyMedical OncologyNeoadjuvant TherapyNeoplasm StagingSocieties, MedicalTreatment Outcome
2008
NCCN Task Force Report: breast cancer in the older woman.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network 2008, 6 Suppl 4: s1-25; quiz s26-7. PMID: 18597715, DOI: 10.6004/jnccn.2008.2004.Peer-Reviewed Original ResearchConceptsBreast cancerOlder patientsOlder womenBreast cancer treatment recommendationsCancer treatment recommendationsSurgical axillary stagingGeriatric assessment toolsPresence of comorbiditiesMetastatic breast cancerBreast cancer patientsRandomized clinical trialsCurative surgeryNCCN institutionsAxillary stagingEndocrine therapyGeriatric oncologySupportive therapyTask ForceMedical oncologyCancer patientsFunctional statusOncology settingTreatment recommendationsClinical trialsMultidisciplinary panel
2006
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM, _ _. HER2 testing in breast cancer: NCCN Task Force report and recommendations. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 3: s1-22; quiz s23-4. PMID: 16813731, DOI: 10.6004/jnccn.2006.2003.Peer-Reviewed Original ResearchConceptsBreast cancerHER2 testingHER2 statusIHC scoreMetastatic settingCopies/cellPredictive factorsHER2 expressionTask force membersEvidence-based consensus approachInvasive breast cancerCancer patient evaluationTask ForceBreast cancer panelGene amplificationBreast cancer tumorsAreas of controversyAdjuvant settingHER2 biologyMedical oncologyPatient evaluationClinical trialsMultidisciplinary panelSurgical oncologyHER2
2005
Economic outcomes of breast cancer survivorship: CALGB study 79804
Hensley ML, Dowell J, Herndon JE, Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Research And Treatment 2005, 91: 153-161. PMID: 15868443, DOI: 10.1007/s10549-004-6497-9.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsBreast cancerMedical oncologistsCancer survivorsMedical oncologyLong-term breast cancer survivorsStage II breast cancerAnnual direct medical costsPatient self-reported dataDisease-free survivorsLong-term outcomesDirect medical costsBreast cancer survivorshipFollow-up variesMedical resourcesMedian annual costPercentage of survivorsLow incomeAdjuvant chemotherapyCancer specialistsCancer survivorshipTumor markersMedical costsYoung survivorsYounger age